Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug;177(1):17-27.
doi: 10.1007/s10549-019-05272-2. Epub 2019 May 27.

Prognostic role of immune infiltrates in breast ductal carcinoma in situ

Xiao-Yang Chen  1   2 , Joe Yeong  1   3 , Aye Aye Thike  1 , Boon Huat Bay  2 , Puay Hoon Tan  4   5
Affiliations
Review

Prognostic role of immune infiltrates in breast ductal carcinoma in situ

Xiao-Yang Chen et al. Breast Cancer Res Treat. 2019 Aug.

Abstract

Purpose: Ductal carcinoma in situ (DCIS) of the breast is often regarded as a non-obligate precursor to invasive breast carcinoma but current diagnostic tools are unable to accurately predict the invasive potential of DCIS. Infiltration of immune cells into the tumour and its microenvironment is often an early event at the site of tumourigenesis. These immune infiltrates may be potential predictive and/or prognostic biomarkers for DCIS. This review aims to discuss recent findings pertaining to the potential prognostic significance of immune infiltrates as well as their evaluation in DCIS.

Methods: A literature search on PubMed was conducted up to 28th January 2019. Search terms used were "DCIS", "ductal carcinoma in situ", "immune", "immunology", "TIL", "TIL assessment", and "tumour-infiltrating lymphocyte". Search filters for "Most Recent" and "English" were applied. Information from published papers related to the research topic were synthesised and summarised for this review.

Results: Studies have revealed that immune infiltrates play a role in the biology and microenvironment of DCIS, as well as treatment response. There is currently no consensus on the evaluation of TILs in DCIS for clinical application.

Conclusions: This review highlights the recent findings on the potential influence and prognostic value of immunological processes on DCIS progression, as well as the evaluation of TILs in DCIS. Further characterisation of the immune milieu of DCIS is recommended to better understand the immune response in DCIS progression and recurrence.

Keywords: Biomarker; DCIS; Immune; Prognostic; Progression; Recurrence.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lee RJ, Vallow LA, McLaughlin SA, Tzou KS, Hines SL, Peterson JL (2012) Ductal carcinoma in situ of the breast. Int J Surg Oncol 2012:12. https://doi.org/10.1155/2012/123549 - DOI
    1. Koh VC, Lim JC, Thike AA, Cheok PY, Thu MM, Tan VK, Tan BK, Ong KW, Ho GH, Tan WJ, Tan Y, Salahuddin AS, Busmanis I, Chong AP, Iqbal J, Thilagaratnam S, Wong JS, Tan PH (2015) Characteristics and behaviour of screen-detected ductal carcinoma in situ of the breast: comparison with symptomatic patients. Breast Cancer Res Treat 152(2):293–304. https://doi.org/10.1007/s10549-015-3472-6 - DOI - PubMed
    1. Cowell CF, Weigelt B, Sakr RA, Ng CKY, Hicks J, King TA, Reis-Filho JS (2013) Progression from ductal carcinoma in situ to invasive breast cancer: revisited. Mol Oncol 7(5):859–869. https://doi.org/10.1016/j.molonc.2013.07.005 - DOI - PubMed - PMC
    1. Wellings SR, Jensen HM (1973) On the origin and progression of ductal carcinoma in the human breast. J Natl Cancer Inst 50(5):1111–1118 - DOI
    1. Doebar SC, van den Broek EC, Koppert LB, Jager A, Baaijens MHA, Obdeijn I-MAM, van Deurzen CHM (2016) Extent of ductal carcinoma in situ according to breast cancer subtypes: a population-based cohort study. Breast Cancer Res Treat 158(1):179–187. https://doi.org/10.1007/s10549-016-3862-4 - DOI - PubMed - PMC

MeSH terms

LinkOut - more resources